Respiratory Syncytial Virus Vaccines
"Respiratory Syncytial Virus Vaccines" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Vaccines or candidate vaccines used to prevent infection with RESPIRATORY SYNCYTIAL VIRUSES.
| Descriptor ID |
D022261
|
| MeSH Number(s) |
D20.215.894.899.730
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Respiratory Syncytial Virus Vaccines".
Below are MeSH descriptors whose meaning is more specific than "Respiratory Syncytial Virus Vaccines".
This graph shows the total number of publications written about "Respiratory Syncytial Virus Vaccines" by people in this website by year, and whether "Respiratory Syncytial Virus Vaccines" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2000 | 1 | 0 | 1 |
| 2001 | 3 | 0 | 3 |
| 2002 | 1 | 0 | 1 |
| 2003 | 1 | 0 | 1 |
| 2007 | 1 | 0 | 1 |
| 2008 | 1 | 0 | 1 |
| 2012 | 1 | 1 | 2 |
| 2014 | 3 | 0 | 3 |
| 2015 | 1 | 0 | 1 |
| 2016 | 3 | 1 | 4 |
| 2017 | 2 | 1 | 3 |
| 2018 | 3 | 0 | 3 |
| 2019 | 1 | 0 | 1 |
| 2020 | 1 | 0 | 1 |
| 2021 | 4 | 0 | 4 |
| 2022 | 2 | 0 | 2 |
| 2023 | 2 | 0 | 2 |
| 2024 | 1 | 2 | 3 |
To return to the timeline,
click here.
Below are the most recent publications written about "Respiratory Syncytial Virus Vaccines" by people in Profiles.
-
Respiratory Syncytial Virus Vaccination in the Adult Pulmonary Patient. Chest. 2024 Nov; 166(5):963-974.
-
Seasonality, Clinical Characteristics, and Outcomes of Respiratory Syncytial Virus Disease by Subtype Among Children Aged <5 Years: New Vaccine Surveillance Network, United States, 2016-2020. Clin Infect Dis. 2024 May 15; 78(5):1352-1359.
-
Medical Costs of Respiratory Syncytial Virus-Associated Hospitalizations and Emergency Department Visits in Children Aged Younger Than 5?Years: Observational Findings from the New Vaccine Surveillance Network, 2016-2019. J Pediatr. 2024 Aug; 271:114045.
-
Early Estimate of Nirsevimab Effectiveness for Prevention of Respiratory Syncytial Virus-Associated Hospitalization Among Infants Entering Their First Respiratory Syncytial Virus Season - New Vaccine Surveillance Network, October 2023-February 2024. MMWR Morb Mortal Wkly Rep. 2024 Mar 07; 73(9):209-214.
-
mRNA vaccines against respiratory viruses. Curr Opin Infect Dis. 2023 10 01; 36(5):385-393.
-
The Efficiency of p27 Cleavage during In Vitro Respiratory Syncytial Virus (RSV) Infection Is Cell Line and RSV Subtype Dependent. J Virol. 2023 05 31; 97(5):e0025423.
-
Evaluation of Recombinant Live-Attenuated Respiratory Syncytial Virus (RSV) Vaccines RSV/?NS2/?1313/I1314L and RSV/276 in RSV-Seronegative Children. J Infect Dis. 2022 12 13; 226(12):2069-2078.
-
Respiratory syncytial virus prevention within reach: the vaccine and monoclonal antibody landscape. Lancet Infect Dis. 2023 01; 23(1):e2-e21.
-
Antibody responses of healthy adults to the p27 peptide of respiratory syncytial virus fusion protein. Vaccine. 2022 01 24; 40(3):536-543.
-
Intranasal and intrapulmonary vaccination with an M protein-deficient respiratory syncytial virus (RSV) vaccine improves clinical signs and reduces viral replication in infant baboons after an RSV challenge infection. Vaccine. 2021 07 05; 39(30):4063-4071.